Hepion (HEPA) COO Sireesh Appajosyula Receives Award

What Happened

• Sireesh Appajosyula, Chief Operating Officer of Hepion Pharmaceuticals (HEPA), received an award of 1,345,500 derivative securities (reported as a grant) on August 19, 2026. The Form 4 shows an acquisition price of $0 and reports the transaction as a derivative award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-19; Form 4 filed: 2026-08-21 (timely filing).
• Transaction type/code: Grant/Award (A) of 1,345,500 derivative securities; acquisition price reported as $0; total reported value $0 (per Form 4 format).
• Vesting: 336,375 options vest immediately upon grant; the remaining 1,009,125 options vest in equal monthly installments over the next six months (per footnote).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding, or cashless exercise noted in the provided details.

Context

• This filing documents a compensation award (derivative grant) to the COO, used for retention/incentive; it is not an open-market purchase or sale. For retail investors, grants like this signal company compensation activity but do not by themselves indicate immediate buying or selling of shares.